HEALTHCARE COSTS AND ECONOMIC BURDEN OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA) AND RELATED MOTOR NEURON DIAGNOSES IN TURKIYE: A REAL-WORLD DATA ANALYSIS
Author(s)
Mustafa KURNAZ, MSc1, Yagmur Faiz, BSc1, Guvenc Kockaya, MSc, PhD, MD2, OZNUR SEYHUN, BSc, MFE, MSc2, Selin Okcun, MSc3, Utku Ceylan, BSc4, Umay Yentur, BSc4, Barış Erdoğan, .4.
1Econix Research, İstanbul, Turkey, 2Econix Research, Tallin, Estonia, 3Health Economist, Econix Research, İstanbul, Turkey, 4Evideep, İstanbul, Turkey.
1Econix Research, İstanbul, Turkey, 2Econix Research, Tallin, Estonia, 3Health Economist, Econix Research, İstanbul, Turkey, 4Evideep, İstanbul, Turkey.
OBJECTIVES: SMA and related motor neuron diagnoses are rare, progressive neuromuscular conditions associated with substantial clinical burden and diverse care needs.This study aimed to assess healthcare costs and cost distribution by age group, diagnosis, care setting, and comorbidity status among patients with SMA and related motor neuron diagnoses in Türkiye.
METHODS: Anonymized patient-level real-world data from a total of 2,691 patients were analyzed based on International Classification of Diseases,10th Revision (ICD-10) codes related to SMA and motor neuron disorders.Total healthcare costs, procedure-related costs, and drug costs were evaluated. Descriptive analyses summarized mean cost per patient overall and by age group, diagnosis, care setting, and comorbidity status.
RESULTS: The total healthcare cost was ₺47.93 million, comprising ₺47.44 million in procedure-related costs and ₺0.49 million in drug costs.Mean per-patient costs by age group were ₺84,601 for ≥85 years, ₺65,238 for 0-17 years, ₺12,869 for 65-84 years, ₺11,418 for 45-64 years, and ₺6,132 for 18-44 years. By diagnosis, mean per-patient costs were ₺146,144 for SMA type I, ₺65,493 for SMA and related syndromes, ₺58,944 for SMA type II, ₺29,795 for unspecified SMA, ₺12,322 for motor neuron disease, and ₺3,808 for other specified SMA.By care setting, mean per-patient costs were ₺294,132 for Intensive Care Unit (ICU) care, ₺38,578 for outpatient care, and ₺2,776 for medical treatment. Mean costs were ₺20,631 among patients with comorbidities and ₺9,708 among those without comorbidities.
CONCLUSIONS: This analysis demonstrates that healthcare costs in SMA and related motor neuron conditions were largely driven by procedure-related expenditures and varied across diagnostic, care setting, and comorbidity subgroups.Higher costs observed in clinically more complex groups, such as older patients or patients with comorbidities, indicate that disease severity and care intensity may be important contributors to economic burden.Overall,these findings provide evidence from routine clinical practice on the cost profile and healthcare resource use of this patient population.
METHODS: Anonymized patient-level real-world data from a total of 2,691 patients were analyzed based on International Classification of Diseases,10th Revision (ICD-10) codes related to SMA and motor neuron disorders.Total healthcare costs, procedure-related costs, and drug costs were evaluated. Descriptive analyses summarized mean cost per patient overall and by age group, diagnosis, care setting, and comorbidity status.
RESULTS: The total healthcare cost was ₺47.93 million, comprising ₺47.44 million in procedure-related costs and ₺0.49 million in drug costs.Mean per-patient costs by age group were ₺84,601 for ≥85 years, ₺65,238 for 0-17 years, ₺12,869 for 65-84 years, ₺11,418 for 45-64 years, and ₺6,132 for 18-44 years. By diagnosis, mean per-patient costs were ₺146,144 for SMA type I, ₺65,493 for SMA and related syndromes, ₺58,944 for SMA type II, ₺29,795 for unspecified SMA, ₺12,322 for motor neuron disease, and ₺3,808 for other specified SMA.By care setting, mean per-patient costs were ₺294,132 for Intensive Care Unit (ICU) care, ₺38,578 for outpatient care, and ₺2,776 for medical treatment. Mean costs were ₺20,631 among patients with comorbidities and ₺9,708 among those without comorbidities.
CONCLUSIONS: This analysis demonstrates that healthcare costs in SMA and related motor neuron conditions were largely driven by procedure-related expenditures and varied across diagnostic, care setting, and comorbidity subgroups.Higher costs observed in clinically more complex groups, such as older patients or patients with comorbidities, indicate that disease severity and care intensity may be important contributors to economic burden.Overall,these findings provide evidence from routine clinical practice on the cost profile and healthcare resource use of this patient population.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD143
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Rare & Orphan Diseases